Glucotrack Stock Today

GCTK Stock  USD 0.34  0.02  6.58%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
GlucoTrack is selling for 0.33629999 as of the 25th of February 2025. This is a 6.58 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.33. GlucoTrack has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of November 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
25th of April 2013
Category
Healthcare
Classification
Health Care
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel. The company has 10.41 M outstanding shares of which 657.54 K shares are currently shorted by private and institutional investors with about 0.01 trading days to cover. More on GlucoTrack

Moving against GlucoTrack Stock

  0.73ANGO AngioDynamicsPairCorr
  0.66IDXX IDEXX LaboratoriesPairCorr
  0.55MMSI Merit Medical Systems Earnings Call TomorrowPairCorr
  0.53A Agilent Technologies Earnings Call TomorrowPairCorr
  0.32ELV Elevance HealthPairCorr

GlucoTrack Stock Highlights

Thematic Ideas
(View all Themes)
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Drugs, Office Supplies, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors)
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.120.15
Significantly Down
Slightly volatile
Total Current Liabilities1.7 M1.7 M
Sufficiently Down
Slightly volatile
Non Current Liabilities Total167.6 K176.4 K
Notably Down
Slightly volatile
Total Assets3.8 M5.6 M
Way Down
Slightly volatile
Total Current Assets3.4 M5.6 M
Way Down
Slightly volatile
Debt Levels
GlucoTrack can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GlucoTrack's financial leverage. It provides some insight into what part of GlucoTrack's total assets is financed by creditors.
Liquidity
GlucoTrack currently holds 196 K in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GlucoTrack has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about GlucoTrack's use of debt, we should always consider it together with its cash and equity.

Other Cashflows From Financing Activities

7,464.15
GlucoTrack (GCTK) is traded on NASDAQ Exchange in USA. It is located in 301 Route 17 North, Rutherford, NJ, United States, 07070 and employs 6 people. GlucoTrack is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.79 M. GlucoTrack conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 10.41 M outstanding shares of which 657.54 K shares are currently shorted by private and institutional investors with about 0.01 trading days to cover. GlucoTrack currently holds about 3.85 M in cash with (6.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25.
Check GlucoTrack Probability Of Bankruptcy
Ownership Allocation
Roughly 97.24 (percent) of GlucoTrack outstanding shares are held by general public with 2.33 % owned by insiders and only 0.43 pct. by outside corporations.
Check GlucoTrack Ownership Details

GlucoTrack Stock Institutional Holders

InstituionRecorded OnShares
Geode Capital Management, Llc2024-09-30
27.2 K
Tower Research Capital Llc2024-09-30
432
Sbi Securities Co Ltd2024-12-31
7.0
Morgan Stanley - Brokerage Accounts2024-12-31
0.0
Cetera Investment Advisers2024-12-31
0.0
Alerus Financial Na2024-12-31
0.0
Ubs Group Ag2024-12-31
0.0
Bank Of America Corp2024-12-31
0.0
View GlucoTrack Diagnostics

GlucoTrack Historical Income Statement

At this time, GlucoTrack's Reconciled Depreciation is quite stable compared to the past year. View More Fundamentals

GlucoTrack Stock Against Markets

GlucoTrack Corporate Management

Erez BenZviGM ProductProfile
Drinda BenjaminVice MarketingProfile
Paul GoodeChief OfficerProfile
MScEE MBAChairman CoFounderProfile
Mark TapsakVice TechnologyProfile
Esq CPAChief OfficerProfile
David BACoFounderProfile
When determining whether GlucoTrack is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlucoTrack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glucotrack Stock. Highlighted below are key reports to facilitate an investment decision about Glucotrack Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(58.20)
Return On Assets
(2.04)
Return On Equity
(19.43)
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.